Showing results (1521-1530 of 3,190) with videos related to

Sort By:
Pageof 319
Translational Oncology|July 10, 2026
Photodynamic therapy in head and neck squamous cell carcinoma: immunomodulation and stromal targeting of cancer-associated fibroblastsJulia Federspiel, Federico Ferro, Jozsef Dudas, et al.
Translational Oncology|March 18, 2026
WDHD1 promotes hepatocellular carcinoma progression by affecting the cell cycle and immune evasionZheng Xiang, Xianfeng Huang, Shimao Zhu, et al.
Translational Oncology|March 18, 2026
Impact of breast reconstruction and different surgical approaches after neoadjuvant therapy on the long-term survival of breast cancer patientsZhaoQi Qiu, YuFeng Zhang, Ting Shou, et al.
Translational Oncology|March 20, 2026
UCHL1 promotes temozolomide resistance in glioblastoma by inhibiting the ubiquitination-mediated degradation of keratin 8Rujuan Zheng, Xi Chen, Guangjuan Xu, et al.
Translational Oncology|April 18, 2026
AAA ATPase TRIP13 is overexpressed in prostate cancer and promotes tumor progressionFarrukh Afaq, Satya S Pathi, Balabhadrapatruni V S K Chakravarthi, et al.
Translational Oncology|April 17, 2026
CD3 and PD-L1 tissue expression have synergistic value in head and neck squamous cell carcinoma prognosisAdrian V Witzleben, Romain Remark, Christian Idel, et al.
Translational Oncology|April 29, 2026
Anoctamin 5 as a protective factor in prostate cancer: Insights from WGCNA, machine learning, and experimental analysis, with a focus on the anoctamin familyJian-She Wang, Li-Li Shao, Dan Yao, et al.
Translational Oncology|May 6, 2026
Mitochondrial RNA helicase DDX28 promotes cell cycle and DNA repair programs and shapes an immunosuppressive microenvironment in acute myeloid leukemiaZi Wang, Yunli Liu, Xinzhu Guan, et al.
Translational Oncology|April 5, 2026
Proof-of-concept study of clinical use of blood-based MAVS biosensor in predicting immunotherapy response in SCLC patientsLuisa Amato, Ines Tavoletta, Caterina De Rosa, et al.
Translational Oncology|April 24, 2026
MUC16 promotes endometrial cancer progression and modulates sensitivity to lapatinib through the ESR1/PI3K/AKT axisYan Yu, Shuqing Lv, Guanlong Li, et al.
Pageof 319